

EGFR+ and ALK+ NSCLC: More options, right choices

Sunday 8th September 2019, 07:00–08:00

Vienna (2016), Hall 8, Fira Gran Via, Barcelona, Spain

Chair's invitation

On behalf of the faculty, I am pleased to invite you to the Pfizer Oncology industry supported symposium **'EGFR+ and ALK+ NSCLC: More options, right choices'**.

As the range of targeted therapies available for oncogene-driven non-small cell lung cancer (NSCLC) continues to grow, physicians need to adjust to a rapidly changing landscape in order to select the best treatment option for each individual patient.

During the symposium, we will review how the treatment algorithms have evolved for patients with advanced EGFR+ and ALK+ NSCLC, and illustrate how treatment paradigms are rapidly shifting by presenting real-world experiences and case studies.

Finally, the faculty will discuss and share perspectives on some of the key criteria and factors that need to be considered to inform treatment decisions in routine clinical practice.

My colleagues and I look forward to welcoming you in Barcelona for what promises to be an interesting and highly educational symposium.

Nicolas Girard, Chair

Oncology Department, Institut Curie, Paris, France

Programme

Chair: **Nicolas Girard (France)**

07:00–07:05	Welcome and introduction	Nicolas Girard (France)
07:05–07:15	More options, right choices	Nicolas Girard (France)
07:15–07:35	EGFR: The dilemma of choice	Daniel Tan (Singapore)
07:35–07:50	ALK: Sequencing our options to maximise outcomes	Alice Shaw (USA)
07:50–08:00	Panel discussion	All faculty, facilitated by Nicolas Girard (France)

Light refreshments will be served prior to the symposium



This meeting is organised and funded by Pfizer.
© 2019 Pfizer Pharma GmbH. All rights reserved.
July 2019. PP-ONC-GLB-0153

This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.

